ATEC CEO Buy Signals Confidence Before Q3 Print

Alphatec Holdings reports third-quarter results on October 30 with the most telling signal coming not from the options market but from inside the company.

CEO Patrick Miles paid $1.01 million out of pocket in September to buy 115,000 shares at $8.81, a discretionary open-market purchase with no 10b5-1 plan attached. The stock has since climbed 29% to $11.37, putting the CEO well in the money heading into the print. Net insider activity over the past 90 days is positive at roughly $934,000, reinforcing the directional signal. That kind of executive conviction, particularly at a company carrying a meaningful short position, gives the bull case a concrete anchor.

The broader positioning picture is more mixed. Short interest is still elevated at 9.4% of the free float, roughly 14 million shares, though bears have been trimming: short positions fell nearly 5.5% over the past week. Borrowing conditions remain easy, with availability at 358% of outstanding short interest and a cost to borrow below 0.5%, so there is no squeeze pressure building in the lending market. Options positioning, however, has turned more defensive into the print. The put/call ratio jumped to 0.36 yesterday, more than two standard deviations above its 20-day average of 0.30, its highest reading in months. That divergence, shorts covering while options traders hedge, is the defining tension in the setup.

The bull-bear debate centres on execution after a difficult first quarter. Bears point to the Q1 revenue miss of roughly $5 million versus consensus and an EPS loss of $0.22 against expectations of $0.02, much of it driven by an 18% decline in EOS imaging revenue. Management responded by cutting full-year revenue guidance to $882 million from $890 million. Bulls counter that the core spine surgery franchise remains genuinely strong: Q1 surgery revenue grew 17% year-on-year, case volume rose 21%, and net new surgeon users were up 23%. Gross margin held at 71% and adjusted EBITDA guidance was left intact at $134 million. The analyst community tilted constructively after the Q1 print, with UBS initiating at Buy with a $15 target and raising it to $16 following results, while BMO and TD Cowen also lifted targets. The consensus mean price target of around $15.80 implies roughly 39% upside from current levels, though that consensus was struck in early August and has not been refreshed since.

Retail attention around the print is notably elevated. ORTEX's Wikipedia and page-view signal for ATEC registered a z-score of 4.76 against its own 90-day history as of mid-October, one of the stronger attention spikes in the data. That heightened interest, combined with an activist register that includes Jennifer Pritzker's 13D filing at 8.9% of the class (as last disclosed in December 2025), gives the shareholder base an unusually concentrated and engaged character ahead of a report that will need to prove the EOS drag is stabilising and the spine business can sustain its growth trajectory.

The print is therefore less a referendum on the spine franchise, which most observers accept as healthy, and more a test of whether EOS imaging has found a floor and whether the full-year guidance cut in Q1 was conservative or still at risk.